Shuttle Pharmaceuticals Holdings, Inc. has announced a significant change in its financial oversight by appointing Bush & Associates CPA LLC as its new independent registered public accounting firm. This decision comes after the dismissal of Forvis Mazars, LLP, which was effective following the filing of the company's Quarterly Report for the fiscal quarter ended September 30, 2026. The move is intended to strengthen the company's financial reporting and compliance processes.

Shuttle Pharmaceuticals, which operates in the pharmaceutical preparations sector, is listed on the Nasdaq under the ticker SHPH. The company is classified under the Standard Industrial Classification (SIC) code 2834, indicating its focus on pharmaceutical products. This transition in auditors is particularly relevant as the pharmaceutical industry faces increasing scrutiny regarding financial practices and regulatory compliance.

According to the recent SEC filing, the Audit Committee of Shuttle Pharmaceuticals' Board of Directors approved the engagement of Bush & Associates on November 2, 2026. The firm will be responsible for auditing the company’s financial statements for the fiscal year ending December 31, 2026, and reviewing its interim financial statements for the following three quarters.

The filing notes that during the fiscal years ended December 31, 2025, and December 31, 2024, as well as the interim period through November 2, 2026, there were no consultations between Shuttle Pharmaceuticals and Bush & Associates regarding accounting principles or audit opinions. Furthermore, there were no disagreements or reportable events between the two parties, which suggests a clean slate as the company moves forward with its new auditing firm.

This change may have implications for various stakeholders, including investors and regulatory bodies, as it reflects the company's commitment to maintaining high standards of financial integrity. The appointment of a new accounting firm can enhance investor confidence, especially in an industry where compliance and transparency are critical.

Looking ahead, Shuttle Pharmaceuticals is expected to continue its focus on financial accuracy and compliance as it works with Bush & Associates. The filing does not specify any further actions or upcoming filings related to this change, but the company will likely keep stakeholders informed about its financial health and reporting processes in future communications.